GAMP 5 status + emerging regulatory developments 2024-2025. STATUS: GAMP 5 2nd Edition (2022) is the current ISPE Guide + adoption progressing in industry; 1st Edition users transitioning; new systems implementing per 2nd Edition. FDA CSA (COMPUTER SOFTWARE ASSURANCE) FINAL GUIDANCE - anticipated 2025-2026; Draft Guidance issued 2022 + has signalled the FDA's risk-based + critical-thinking + assurance-by-assessment approach for non-product-and-process-related software; GAMP 5 2nd Edition critical-thinking emphasis aligns; FINAL GUIDANCE will codify FDA's expectations + may reduce some prescriptive validation testing for low-risk systems. AI/ML IN PHARMA + BIOTECH: 2024-2025 ISPE GAMP Community of Practice publications on AI/ML validation + 2024 ISPE AI/ML in GxP whitepaper; FDA AI/ML SaMD Action Plan + Predetermined Change Control Plan (PCCP); EU AI Act compliance for pharma AI systems (in scope as high-risk where applicable); IMDRF AI Working Group international harmonisation; GAMP 5 application to LLM-based pharma workflows (drug discovery + clinical decision support + regulatory submissions + patient engagement). CLOUD + SaaS DEEPENING: pharma cloud adoption accelerating; shared-responsibility maturity + cloud-native validation patterns + SaaS lifecycle alignment with GAMP 5. DATA INTEGRITY REMOTE INSPECTIONS: post-pandemic + ongoing FDA + EMA + MHRA remote inspection methodologies + emphasis on audit-trail review + electronic-records-completeness + ALCOA+ in cloud context. SUSTAINABILITY + CSRD: emerging focus on sustainability + ESG + carbon footprint of GxP IT systems aligned with EU Corporate Sustainability Reporting Directive.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.